Effect of GLP-1 on Angiogenesis

NCT02686177 · Completed

Last updated 2026-05-28

This clinical trial is testing how the medication liraglutide, a GLP-1 treatment, affects a protein called ANGPTL4 in people with type 2 diabetes over a 4-week period.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 50 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-05 · est. completion 2021-05

Where 1 site · France

What this study is testing ClinicalTrials.gov NCT02686177 ↗

Description as written by the study sponsor.

GLP-1 receptor agonists are introduced in the treatment of type 2 Diabetes (T2D) and their efficacy is documented. However, safety aspects are also important to evaluate with respect to micro and macrovascular complications associated with T2D. Few studies have properly addressed the role of GLP-1-based therapies in regulating vascular integrity and angiogenesis. The study evaluate the impact of one-month treatment Liraglutide on both ANGPT2 and ANGLPT4 levels and endothelial circulating progenitor cells, angiogenesis biomarkers in type 2 diabetic patients.

Treatments tested

Liraglutide Drug
Metformin or sulfonylurea Drug

Main thing measured	Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group
Sponsor	Assistance Publique - Hôpitaux de Paris
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02686177 ↗